15001 Durable efficacy of certolizumab pegol dosed at 400 mg every two weeks over 128 weeks in patients with plaque psoriasis enrolled in three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

Abstract

Background: The Fc-free, PEGylated, anti–tumor necrosis factor certolizumab pegol (CZP) has demonstrated efficacy and safety in moderate to severe plaque psoriasis (PSO). Here, we report long-term response in patients with PSO receiving CZP 400 mg every 2 weeks (q2w) for up to 128 weeks.